MI-MAGICOvarian cancer prevention in Michigan
Menu

MI-MAGIC / Clinical review

How this information is reviewed

Every clinical claim on this site traces to a published study, and every patient-facing sentence follows a reviewed source document. This page shows the review gates and lists the sources.

Three review gates

Patient information

Patient wording follows the Michigan patient decision aid, adapted from British Columbia's Fallopian Tube Removal Decision Aid - materials in clinical use in BC's province-wide program since the 2010s. Content review by the program's clinical team is complete; named publication review is the final step before formal launch.

Provider training

Every training module is versioned, and the platform will not publish a module until its clinical review is recorded. Unreviewed material cannot reach providers - the gate is enforced by the system, and it is why no modules are public yet.

Evidence and updates

Every number on this site traces to a published study, listed below, and risk figures are stated conservatively: the site says the risk is cut “at least in half” where individual studies report 49% to 80% reductions. Named reviewers, review dates, and the update schedule will be added here at launch.

Sources

The plain-language version of what these studies found is on the evidence page.

Where ovarian cancer starts, and the missed opportunity

  1. Piek JM, Schauwaert J, Burney Ellis L, et al. Opportunistic salpingectomy for prevention of tubo-ovarian carcinoma: the ESGO consensus statements. JAMA. 2026;335(10):894-902.
  2. American College of Obstetricians and Gynecologists. Opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. ACOG Committee Opinion No. 774. Obstetrics & Gynecology. 2019;133(4):e279-e284.
  3. American College of Obstetricians and Gynecologists. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 182. Obstetrics & Gynecology. 2017.
  4. Tischer KM, Islam NS, McGree ME, Tapia AL, Hanley GE, Huntsman D, et al. Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy. Gynecologic Oncology. 2025.
  5. Cook IC, Podwika SE, Hallowell PT, Conaway MR, Landen CN. The potential for opportunistic salpingectomy to reduce ovarian cancer in women undergoing non-gynecologic surgery. Gynecologic Oncology Reports. 2025.

How much removal lowers risk

  1. Falconer H, Yin L, Grönberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. Journal of the National Cancer Institute. 2015;107(2):dju410.
  2. Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. European Journal of Cancer. 2016;55:38-46.
  3. Hanley GE, Pearce CL, Talhouk A, et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Network Open. 2022.
  4. Sowamber R, Mei AJ, Kaur P, et al. Serous ovarian cancer following opportunistic bilateral salpingectomy. JAMA Network Open. 2026.

Safety

  1. Hanley GE, Kwon JS, Finlayson SJ, Huntsman DG, Miller D, McAlpine JN. Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. American Journal of Obstetrics and Gynecology. 2018.
  2. Tomasch G, Lemmerer M, Oswald S, Uranitsch S, Schauer C, et al. Prophylactic salpingectomy for prevention of ovarian cancer at the time of elective laparoscopic cholecystectomy. 2020.

Prevention efficiency and the colonoscopy comparison

  1. Wright JD, Chen L, Tymm C, Xu X, Ferris JS, et al. Population-level reduction in ovarian cancer through performance of opportunistic salpingectomy at the time of cholecystectomy. Annals of Surgery. 2025.
  2. Bretthauer M, Loberg M, Wieszczy P, et al. (NordICC trial). Effect of colonoscopy screening on risks of colorectal cancer and related death. New England Journal of Medicine. 2022;387:1547-1556.

Cost-effectiveness

  1. Adjei NN, Yeh PG, Haas A, Sun CC, Zhao H, Stone R, et al. Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: a cost-effectiveness analysis. International Journal of Gynecological Cancer. 2026.
  2. Matsuo K, Chen L, Matsuzaki S, et al. Opportunistic salpingectomy at the time of laparoscopic cholecystectomy for ovarian cancer prevention: a cost-effectiveness analysis. Annals of Surgery. 2022.
  3. Kather A, Arefian H, Schneider C, Hartmann M, Runnebaum IB. Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: a cost-effectiveness modeling study. PLOS Medicine. 2025.

Source documents for patient materials

  1. Fallopian Tube Removal Decision Aid. British Columbia Ovarian Cancer Research Program (OVCARE) / BC Cancer.
  2. Opportunistic Salpingectomy Consenting Handout for providers. British Columbia OVCARE / BC Cancer.

Spotted an error, or have a question about a source? Write to michigan-magic@umich.edu.